Mood & Emotion (우울조울병)

Korean Society for Affective Disorders (대한우울조울병학회)
권호 표지

Korean Medication Algorithm for Bipolar Disorder 2018 : Safety and Tolerability

한국형 양극성 장애 약물치료 알고리듬 2018 : 안정성과 내약성

  • Sohn, InKi (Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation) ;
  • Bahk, Won-Myong (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Yoon, Bo-Hyun (Department of Psychiatry, Naju National Hospital) ;
  • Jon, Duk-In (Department of Psychiatry, Sacred Heart Hospital, Hallym University) ;
  • Seo, Jeong Seok (Department of Psychiatry, School of Medicine, Konkuk University) ;
  • Kim, Won (Department of Psychiatry, Seoul Paik Hospital, College of Medicine, Inje University) ;
  • Lee, Jung Goo (Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University and Paik Institute for Clinical Research) ;
  • Woo, Young Sup (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Jeong, Jong-Hyun (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Kim, Moon-Doo (Department of Psychiatry, Jeju National University Hospital) ;
  • Jung, Young-Eun (Department of Psychiatry, Jeju National University Hospital) ;
  • Shim, Se-Hoon (Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University) ;
  • Song, Hoo-Rim (Department of Psychiatry, Myongji Hospital) ;
  • Min, Kyung Joon (Department of Psychiatry, College of Medicine, Chung-Ang University)
  • 손인기 (계요의료재단 계요병원 정신건강의학과) ;
  • 박원명 (가톨릭대학교 의과대학 정신과학교실) ;
  • 윤보현 (국립나주병원 정신건강의학과) ;
  • 전덕인 (한림대학교 의과대학 성심병원 정신건강의학과) ;
  • 서정석 (건국대학교 의학전문대학원 충주병원 정신건강의학과) ;
  • 김원 (인제대학교 의과대학 서울백병원 정신건강의학과) ;
  • 이정구 (인제대학교 의과대학 해운대백병원 정신건강의학과 및 백인제기념 임상의학연구소) ;
  • 우영섭 (가톨릭대학교 의과대학 정신과학교실) ;
  • 정종현 (가톨릭대학교 의과대학 정신과학교실) ;
  • 김문두 (제주대학교병원 정신건강의학과) ;
  • 정영은 (제주대학교병원 정신건강의학과) ;
  • 심세훈 (순천향대학교 의과대학 천안병원 정신건강의학과) ;
  • 송후림 (명지병원 정신건강의학과) ;
  • 민경준 (중앙대학교 의과대학 정신건강의학교실)
  • Received : 2018.10.06
  • Accepted : 2018.10.15
  • Published : 2018.11.30

⟨ Previous Next ⟩

Abstract

Objectives : Treatment for bipolar disorder is often complicated by various clinical situations. We undertook a survey of expert opinions to facilitate clinical decisions in special situations such as weight gain, metabolic syndrome, hyperprolactinemia, genetic counseling, and treatment adherence. Methods : A written survey that asked treatment strategies related to safety and tolerability, was prepared focused on weight gain, antipsychotic related hyperprolactinemia, lamotrigine related skin rash, treatment non-adherence and genetic counseling. Sixty-one experts of the review committee completed the survey. Results : In the case of weight gain related to medications, experts preferred exercise and education for diet-control. First chosen medications were lamotrigine, aripiprazole and ziprasidone. Recommendations based on expert survey results for treatment of bipolar patients in other special situations are outlined. Conclusion : With limitation of expert opinions, authors hope that results of this study provide valuable information to make clinical decisions about treatment of bipolar disorder in complicated situations.

Keywords

Acknowledgement

Supported by : 대한우울.조울병학회, 대한정신약물학회

References

  1. Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013;170:265-274. https://doi.org/10.1176/appi.ajp.2012.12050620
  2. Col SE, Caykoylu A, Karakas Ugurlu G, Ugurlu M. Factors affecting treatment compliance in patients with bipolar I disorder during prophylaxis: a study from Turkey. Gen Hosp Psychiatry 2014;36:208-213. https://doi.org/10.1016/j.genhosppsych.2013.11.006
  3. The Executive Committee of Korean Medication Algorithm Project for Bipolar Disorder. The Korean Medication Guideline for Bipolar Disorder 2002. Choon-Ang-Moonwhasa, Seoul;2002.
  4. The Executive Committee of Korean Medication Algorithm Project for Bipolar Disorder. The Korean Medication Guideline for Bipolar Disorder 2006. Choon-Ang-Moonwhasa, Seoul;2006.
  5. Min KJ, Bahk WM, Yoon BH, Kim W, Kim BS, Lee JG, et al. Korean Medication Algorithm for Bipolar Disorder 2010: Introduction. Korean J Psychopharmacol 2011;22:142-153.
  6. Woo YS, Lee JG, Jeong JH, Kim MD, Sohn I, Shim SH, et al. Korean Medication Algorithm Project for Bipolar Disorder: third revision. Neuropsychiatr Dis Treat 2015;26;11:493-506.
  7. McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry 2012;24:69-81.
  8. National Institute for Health and care Excellence. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. 2014. https://www.nice.org.uk/guidance/cg185.
  9. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35:1520-1530. https://doi.org/10.1038/npp.2010.21
  10. Raison CL, Klein HM. Psychotic mania associated with fenfluramine and phentermine use. Am J Psychiatry 1997;154:711.
  11. Hussain SS, Bloom SR. The pharmacological treatment and management of obesity. Postgrad Med 2011;123:34-44. https://doi.org/10.3810/pgm.2011.01.2243
  12. Gadde KM, Xiong GL. Bupropion for weight reduction. Expert Rev Neurother 2007;7:17-24. https://doi.org/10.1586/14737175.7.1.17
  13. Kemp DE, Karayal ON, Calabrese JR, Sachs GS, Pappadopulos E, Ice KS, et al. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. Eur Neuropsychopharmacol 2011;22:123-131.
  14. Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR. Impact of lamotrigine and lithium on weight in obese and non- obese patients with bipolar I disorder. Am J Psychiatry 2006;163:1199-1201. https://doi.org/10.1176/ajp.2006.163.7.1199
  15. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-1773. https://doi.org/10.1001/jama.2009.1549
  16. Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-1019. https://doi.org/10.4088/JCP.v63n1110
  17. Seo HJ, Chiesa A, Lee SJ, Patkar AA, Han C, Masand PS, et al. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol 2011;34:39-47. https://doi.org/10.1097/WNF.0b013e3182055c07
  18. Lorberg B, Youssef NA, Bhagwagar Z. Lamotrigine-associated rash: to rechallenge or not to rechallenge? Int J Neuropsychopharmacol 2009;12:257-265. https://doi.org/10.1017/S1461145708009504
  19. Woo YS, Bahk WM, Park YM, Chung S, Yoon BH, Won S, et al. Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder. Int Clin Psychopharmacol 2016;31:275-286. https://doi.org/10.1097/YIC.0000000000000136
  20. Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 2008;22(2 Suppl):90-97. https://doi.org/10.1177/0269881107087373